Dopamine control of prolactin secretion in multiple endocrine neoplasia type I

Clin Invest Med. 1984;7(3):161-4.

Abstract

Taking advantage of high prevalence of prolactinomas in Newfoundland families with variant multiple endocrine neoplasia Type I (MEN I), we studied the control of prolactin secretion by dopamine in family members with prolactinomas (n = 6), family members who have hyperparathyroidism but no prolactinomas (n = 6), as well as healthy members (n = 8) in unaffected sibships. Four unrelated patients with empty sella syndrome were also studied as sella size controls for the prolactinoma group. Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Family members with hyperparathyroidism but no prolactinoma (and to a lesser degree the empty sella syndrome group) showed much less post-infusion rebound than controls. We conclude that family members genetically predisposed to prolactinoma (and patients with empty sella syndrome) may exhibit subtle abnormalities in dopaminergic control of prolactin secretion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / genetics
  • Adenoma / metabolism*
  • Adult
  • Dopamine / pharmacology*
  • Dopamine / physiology
  • Empty Sella Syndrome / blood
  • Female
  • Humans
  • Hyperparathyroidism / blood
  • Hyperparathyroidism / genetics
  • Multiple Endocrine Neoplasia / genetics
  • Multiple Endocrine Neoplasia / metabolism*
  • Pituitary Neoplasms / genetics
  • Pituitary Neoplasms / metabolism*
  • Prolactin / metabolism*

Substances

  • Prolactin
  • Dopamine